Collegium Pharmaceutical: A Promising Small-Cap Drug Manufacturer with Diversified Portfolio

Tuesday, Mar 31, 2026 7:37 am ET1min read
COLL--

Collegium Pharmaceutical (COLL) is a small-cap drug manufacturer that has recently acquired Corium Therapeutics Holdings for $650 million in cash and up to $135 million in earn-outs. The acquisition will diversify COLL's topline and contribute to its revenue base through the late 2030s. COLL is also partnering with Boston Legacy FC to make its home games more comfortable and inclusive for fans. The company offers a range of pain management medicines, including Jornay PM, Belbuca, and Nucynta ER.

Collegium Pharmaceutical: A Promising Small-Cap Drug Manufacturer with Diversified Portfolio

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet